Why the study?
Guidelines recommend aggressive hypertension management, but recent evidence suggested potential harm with low blood pressure targets in patients with peripheral artery disease.
Is a history of hypertension or out-of-target systolic blood pressure associated with increased risk of MACE and MALE in patients with symptomatic peripheral artery disease?
RCT (n=13,885)
Is a history of hypertension or out-of-target systolic blood pressure associated with increased risk of MACE and MALE in patients with symptomatic peripheral artery disease?
In patients with symptomatic PAD, both high (>125 mmHg) and low (≤125 mmHg) systolic blood pressures are associated with an increased risk of MACE, suggesting potential harm with overly aggressive blood pressure targets.
Background: Current guidelines recommend aggressive management of hypertension. Recent evidence suggested potential harm with low blood pressure targets in patients with peripheral artery disease. We investigated the association of a history of hypertension and office systolic blood pressure (SBP) with major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs). Methods and Results: The EUCLID trial (Examining the Use of Ticagrelor in Peripheral Artery Disease) included 13 885 participants with symptomatic peripheral artery disease; median follow-up was 30 months. Cox proportional hazards regression was used to calculate hazard ratios (HRs) for any MACE, MALE, and MALE including lower extremity revascularization. A clinical history of arterial hypertension was present in 10 857 (78%) participants, and these participants were older and more likely to be female when compared with the 3026 (22%) patients without hypertension. In patients with a history of hypertension, the adjusted hazard ratio for MACE was 0.94, 95% CI, 0.82–1.08; P =0.39, and the adjusted hazard ratio for MALE was 1.08, 95% CI, 0.96–1.23; P =0.21. During follow-up, average SBP was 135 mm Hg (125–145). Every 10 mmHg increase in SBP>125 mmHg was associated with an increased risk of MACE (HR, 1.10 [95% CI, 1.06–1.14]; P <0.001), a marginally increased risk of MALE (HR, 1.07 [95% CI, 1.00–1.15]; P =0.062), and an increased risk of MALE/lower extremity revascularization (HR, 1.08 [95% CI, 1.04–1.11]; P <0.001). Every decrease in 10 mmHg SBP ≤125 mmHg was associated with an increased risk of MACE (HR, 1.19 [95% CI, 1.09–1.31]; P <0.001) but not MALE or MALE/lower extremity revascularization (HR, 1.02 [95% CI, 0.84–1.23], P =0.824; HR, 1.04 [95% CI, 0.95–1.13], P =0.392, respectively). Conclusions: History of hypertension was not associated with higher hazard for MACE or MALE in patients with peripheral artery disease. In contrast, there was a higher hazard of MACE in patients with out-of-target low and high SBP. High but not low SBP was associated with an increased risk of ischemic limb events. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01732822.
No takes yet. Share an insight, caveat, or question.
Fudim et al. (2020) conducted an RCT in symptomatic peripheral artery disease (n=13,885). History of hypertension and office systolic blood pressure vs. No history of hypertension and in-target systolic blood pressure was evaluated on major adverse cardiovascular events (MACEs) (HR 0.94, 95% CI 0.82-1.08, p=0.39).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: